MedTrace Logo

Heterogeneity and Evolution of hepatoceLlular Carcinoma in Post-transplant HCC Recurrence

NCT04506398 · Status: UNKNOWN · Type: OBSERVATIONAL · Enrollment: 40

Last updated 2021-06-24

No results posted yet for this study

Summary

Objective of Study: This study will evaluate the heterogeneity and evolution pathway between primary HCC and tumor relapse after liver transplant.

According to the "Seed-Soil" theory, the primary hypothesis of this study is that HCC patients with different molecular-subtype experience altered different pattern of post-transplant recurrence, thus may have altered postoperative Recurrence-Free Survival (RFS). Because the donors' liver construct different microenvironment for CTC(circulating tumor cells) colonization. The investigators design this translational study to ①explore potential high recurrent risk HCC molecular-subtypes which might benefit from neoadjuvant systematic therapy or early adjuvant systematic therapy;②identify the molecular subtype heterogeneity of primary and recurrent HCC to guide the precision medicine.

Conditions

  • Hepatocellular Carcinoma Recurrent
  • Liver Transplant; Complications

Interventions

PROCEDURE

liver transplant

Liver transplantation for hepatocellular carcinoma has the potential to eliminate both the tumor as well as the underlying cirrhosis and is the ideal treatment for HCC in cirrhotic liver as well as massive HCC in noncirrhotic liver.

DIAGNOSTIC_TEST

ctDNA

Circulating Tumor DNA Correlates With Microvascular Invasion and Predicts Tumor Recurrence of Hepatocellular Carcinoma

DIAGNOSTIC_TEST

whole exome sequencing

xome sequencing analysis of liver tumors could reveal mutational signatures associated with specific risk factors of recurrence.

Sponsors & Collaborators

  • RenJi Hospital

    lead OTHER

Principal Investigators

  • Hao Feng, M.D., Ph.D. · Dept. of Liver surgery, Renji Hospital, Medical School of Shanghai Jiaotong University

Eligibility

Min Age
18 Years
Max Age
80 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2020-09-10
Primary Completion
2021-08-31
Completion
2022-08-31

Countries

  • China

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04506398 on ClinicalTrials.gov